Andy Chen
Stock Analyst at Wolfe Research
(4.58)
# 960
Out of 5,004 analysts
72
Total ratings
63.8%
Success rate
26.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgraded: Buy | $180 | $115.81 | +55.43% | 5 | Sep 10, 2026 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | $605 | $513.21 | +17.89% | 3 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $548 → $557 | $522.38 | +6.63% | 5 | Aug 3, 2026 | |
| SYRE Spyre Therapeutics | Downgraded: Hold | n/a | $87.09 | - | 2 | Jul 28, 2026 | |
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $43.81 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $12.16 | -25.99% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $18.39 | +46.82% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $44 | $31.48 | +39.77% | 4 | Jun 14, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $94.87 | +43.35% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $88 | $33.34 | +163.95% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $15.72 | +205.34% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $90.71 | +8.04% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $1.57 | +345.86% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $32.99 | +27.31% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $34.00 | +38.24% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $12.12 | +98.02% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $962.22 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.26 | +298.77% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $173 | $121.55 | n/a | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $249.59 | n/a | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $66.28 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $51.70 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $124.44 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $85.49 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $27.50 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $20.66 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $55.70 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $36.13 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $6.31 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
Kymera Therapeutics
Sep 10, 2026
Upgraded: Buy
Price Target: $180
Current: $115.81
Upside: +55.43%
Madrigal Pharmaceuticals
Aug 4, 2026
Upgraded: Buy
Price Target: $605
Current: $513.21
Upside: +17.89%
Vertex Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $548 → $557
Current: $522.38
Upside: +6.63%
Spyre Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $87.09
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $43.81
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $12.16
Upside: -25.99%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $18.39
Upside: +46.82%
Celldex Therapeutics
Jun 14, 2026
Reiterated: Buy
Price Target: $44
Current: $31.48
Upside: +39.77%
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $94.87
Upside: +43.35%
Vera Therapeutics
Jun 2, 2026
Reiterated: Buy
Price Target: $88
Current: $33.34
Upside: +163.95%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $15.72
Upside: +205.34%
Apr 8, 2026
Reiterated: Buy
Price Target: $98
Current: $90.71
Upside: +8.04%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.57
Upside: +345.86%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $32.99
Upside: +27.31%
Apr 6, 2026
Reiterated: Buy
Price Target: $47
Current: $34.00
Upside: +38.24%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $12.12
Upside: +98.02%
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $962.22
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $3.26
Upside: +298.77%
Aug 14, 2025
Reiterated: Buy
Price Target: $54 → $173
Current: $121.55
Upside: n/a
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $249.59
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $66.28
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $51.70
Upside: n/a
Mar 17, 2025
Reiterated: Buy
Price Target: $84
Current: $124.44
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $85.49
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $27.50
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $20.66
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $55.70
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $36.13
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $4
Current: $6.31
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a